GLP-1 Benefits Beyond Weight Loss: What the 2026 Evidence Says
5 min read
CTO & Co-Founder of miora. Stanford Biodesign, ex-Tesla.
The GLP-1 conversation is shifting in 2026. Weight loss is still the visible outcome but the trial data is increasingly showing other effects - cardiovascular event reduction, kidney protection, signals on alcohol and tobacco use, and emerging cartilage findings. This is what the 2026 evidence actually says and what your protocol tracker can surface beyond the scale.
Topics on this page
Cardiovascular event reduction (SELECT trial, semaglutide) is the strongest non-weight benefit with the most evidence. The effect is meaningful and goes beyond what weight loss alone explains.
Kidney function preservation (FLOW trial, semaglutide) is established in chronic kidney disease populations. Implications for non-CKD populations are still being characterized.
Addiction signals (alcohol, tobacco, gambling) are emerging in observational data and dedicated trials. The mechanism is the same dopaminergic modulation that explains anhedonia; the same circuit can also reduce craving signals.
Through 2023 and 2024 the GLP-1 conversation was dominated by weight loss numbers. In 2025 and 2026 the conversation broadened. The cardiovascular outcome trials (SELECT for semaglutide, multiple ongoing trials for tirzepatide and retatrutide) demonstrated meaningful reductions in major adverse cardiovascular events that go beyond what would be expected from the weight loss alone. The FLOW trial showed kidney benefits in chronic kidney disease populations. Anecdotal reports of reduced cravings for alcohol, tobacco, and other substances have begun to attract serious research attention. The cartilage findings (Max #3, 186-score Reddit thread) are emerging but real. This guide is the practical view of what the 2026 evidence says, what is hype, and what your tracking can surface.
The SELECT trial (semaglutide 2.4 mg weekly in adults with established cardiovascular disease and overweight or obesity but without diabetes) was the landmark 2023 study. Over a median follow-up of 39.8 months, semaglutide reduced major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 20% compared to placebo. The number-needed-to-treat over the trial duration was approximately 67.
The mechanism is partly explained by weight loss but not fully. Semaglutide-treated patients had improvements in blood pressure, lipid markers, and inflammatory markers that exceeded what the weight loss alone would predict. The implication is that the cardiovascular benefit is partly direct (independent of weight) and partly mediated through the metabolic changes.
SURMOUNT-MMO and other tirzepatide cardiovascular outcome trials are ongoing. The expectation in the literature is that tirzepatide will show similar or larger cardiovascular benefits, but the data is not yet final. Retatrutide cardiovascular outcomes are in earlier trials.
What this means for tracking: blood pressure, lipid panel trends, and inflammatory markers (hsCRP) are part of the operative data on any GLP-1 protocol. miora's quarterly lab integration surfaces the trends across panels.
The FLOW trial (semaglutide 1.0 mg weekly in adults with type 2 diabetes and chronic kidney disease) was published in 2024 and demonstrated approximately 24% reduction in a composite kidney outcome - including persistent eGFR decline, kidney failure, and death from kidney-related causes. The trial was stopped early for efficacy after a median 3.4-year follow-up.
The kidney protection is partly explained by glycemic improvement, partly by blood pressure improvement, and partly by direct effects on glomerular hemodynamics that are still being characterized. For populations with diabetes-related kidney disease, GLP-1s are increasingly being considered part of the kidney-protective protocol alongside SGLT-2 inhibitors and renin-angiotensin system blockers.
For non-CKD populations, the implications are less clear. The cardiovascular benefit in non-diabetic SELECT populations did not show the same kidney-specific outcomes because the population did not have advanced kidney disease. Whether GLP-1s prevent or delay kidney disease in a population without baseline kidney compromise is still being studied.
For tracking: eGFR, urine albumin-creatinine ratio (UACR), and standard kidney function markers on quarterly labs surface the kidney trend. miora flags meaningful trends.
One of the most striking patterns in observational GLP-1 use has been the consistent community reports of reduced cravings for alcohol, tobacco, gambling, and other substances. The mechanism is plausible: GLP-1 agonists modulate the mesolimbic dopaminergic system, and the same circuit that drives food-noise also drives other reward-seeking behaviors.
The evidence in 2026 is at multiple stages. Observational and electronic-health-record studies have consistently shown reduced alcohol use and tobacco use in patients on GLP-1s. Dedicated randomized trials are ongoing. The mechanism studies (animal models, neuroimaging) are accumulating. None of this has translated into formal FDA indications for addiction treatment as of mid-2026, but several trials are in the pipeline.
For tracking purposes, if reduced cravings are part of why you are running the protocol or are an emergent benefit, the daily log can capture them. miora's daily check can include 'cravings 1-5' as an additional dimension when relevant. Specific substances can be tracked separately. The pattern surfaces over weeks.
One of the emerging GLP-1 benefits that has attracted community attention - including a high-engagement Reddit thread (186 score) - is the effect on cartilage and joint health. The mechanism is partly indirect (weight loss reduces joint load, particularly for knee and hip osteoarthritis) and partly direct (anti-inflammatory effects and possibly direct effects on chondrocytes).
The clinical evidence in 2026 is preliminary. A few studies have shown improved knee osteoarthritis symptoms and possibly slower structural progression in GLP-1-treated patients with obesity and knee OA. The findings are consistent enough to warrant attention but not definitive enough to support GLP-1 prescription for joint indications alone.
For tracking purposes, anyone running a GLP-1 with joint considerations - knee pain, hip pain, exercise tolerance limitations from joints - can include a daily joint score in the rubric. miora's daily check accommodates the addition. The trend over a 6-month cycle is the operative signal.
The extended log for capturing GLP-1 benefits beyond weight loss includes:
Blood pressure. Daily morning if relevant; weekly if not. Trend over the protocol is what matters.
Resting heart rate. From wearable. Useful baseline regardless of compound.
Quarterly labs. CMP, lipid panel, HbA1c, eGFR, UACR, hsCRP. Trends across panels.
Cravings score. If relevant. Daily 1-5 on whichever substance is the operative one.
Joint or recovery score. If relevant. Daily 1-5 on the indicated joint or area.
Standard six-dimension mood rubric. Continues to apply.
Standard side-effect curve. Continues to apply.
Smoothed weight. Continues to apply.
The point of the extended log is not to track more for the sake of it; it is to surface the benefits that the weight log alone does not show. A user whose primary motivation is weight loss but who is also experiencing reduced alcohol cravings should have the cravings data to surface the pattern.
The GLP-1 conversation in 2026 includes a substantial amount of speculation about potential benefits. Useful to separate evidence levels.
Strong evidence (RCT-supported, FDA-recognized): Weight loss, glycemic control in type 2 diabetes, cardiovascular event reduction in established cardiovascular disease populations (semaglutide via SELECT), kidney protection in diabetic CKD (semaglutide via FLOW).
Moderate evidence (RCT or strong observational support): Blood pressure reduction, lipid improvement, hsCRP reduction, alcohol use reduction.
Emerging evidence (observational, mechanism plausible, RCTs in progress): Tobacco use reduction, gambling and other addiction-related craving reduction, knee osteoarthritis symptom improvement, sleep apnea improvement, NAFLD/NASH improvement.
Speculative (anecdotal, mechanism unclear): Alzheimer disease risk modification (some trials underway), Parkinson disease progression, depression as a primary indication, longevity extension.
The first three categories are worth tracking proactively if the indication is relevant. The fourth is too early to drive any protocol decision.
The daily check can be extended to include the non-weight dimensions when relevant. A representative evening text for a user on Zepbound with concurrent knee osteoarthritis and alcohol-use considerations might read: 'Zep day 2: nausea 2 / fatigue 2 / GI fine / 64 oz / 105 g / BP 124/78 / knee pain 2 / cravings 1 (alcohol) / weight 192.6.' miora parses the dimensions, logs each separately, and surfaces them in the weekly summary.
The weekly summary becomes multi-dimensional: 'Smoothed weight down 1.1 lb week-over-week. BP averaged 122/76 vs baseline 134/84 - meaningful improvement at 8 weeks in. Knee pain averaged 2.1 vs baseline 3.4 - meaningful improvement, possibly related to weight or possibly to direct GLP-1 effect. Alcohol cravings averaged 1.3 vs baseline 3.0 - substantial reduction worth noting in your next clinician visit.' The full picture of what the protocol is doing surfaces in the structured log.
For lab integration, quarterly panels feed in the same way. eGFR, lipid panels, and hsCRP trends are surfaced alongside the weight trend. The clinician-ready summary on demand pulls all of the data together.
Three boundaries.
This guide does not recommend GLP-1 use for indications beyond their FDA-approved use. Semaglutide and tirzepatide are approved for specific indications; off-label use for cardiovascular prevention, addiction treatment, or joint indications belongs with your prescriber and is not endorsed here.
This guide does not interpret your specific labs or symptoms. The patterns described are population-level findings; your individual situation requires clinical interpretation.
The guide does not predict outcomes. Cardiovascular benefit in SELECT was 20% relative risk reduction - meaningful at the population level, not a guarantee for any individual. Same for kidney, joint, and other findings. This content is for informational purposes only and is not medical advice. GLP-1 medications require prescription and clinician supervision.
107
